Publication at First Faculty of Medicine |
2020
Abstract
ALK mutations were first described in NSCLC in 2007. The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by ALK inhibitors.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of ALK such as an EML4-ALK translocation. Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors.